GPR55: Current knowledge and future perspectives of a purported "type-3" cannabinoid receptor

Current Medicinal Chemistry

Volumn 17, Issue 14, 2010, Pages 1411-1429

  Moriconi, A ^a   Cerbara, I ^b   Maccarrone, M ^c,d,e   Topai, A ^b  

^a Research Center   (Italy)

^b Via Della Ricerca Scientifica Snc   (Italy)

^c UNIVERSITY OF TERAMO   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cannabinoid receptors; Downstream signalling pathway; Functional selectivity; GPCR; GPR55

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; ADENOSINE 5' O (3 THIOTRIPHOSPHATE); ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 3 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; DRONABINOL; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE; NOLADIN ETHER; O 1602; OLEYLETHANOLAMIDE; PALMYTOYLETHANOLAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CDC42; RAC PROTEIN; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; RIMONABANT; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRODHAMINE;

DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; LIGAND BINDING; NONHUMAN; PROTEIN MOTIF; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

HUMANS; PATENTS AS TOPIC; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 77950630872     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790980069     Document Type: Review

References (76)

1. Gaoni, Y.; Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 1964, 86, 1646.
2. Hill, S. J. G-protein-coupled receptors: past, present and future. Br. J. Pharmacol. 2006, 147, S27.
3. Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346, 561.
4. Di Marzo, V.; Bifulco, M.; De Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discov. 2004, 3, 771. (Pubitemid 39242829)
5. Wagner, J. A.; Varga, K.; Jarai, Z.; Kunos, G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 1999, 33, 429.
6. Járai, Z.; Wagner, J. A.; Varga, K.; Lake, K. D.; Compton, D. R.; Martin, B. R.; Zimmer, A. M.; Bonner, T. I.; Bucley, N. E.; Mezey, E.; Razdan, R. K.; Zimmer, A.; Kunos, G. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA 1999, 96, 14136.
7. Sawzdargo, M.; Nguyen, T.; Lee, D. K.; Lynch, K. R.; Cheng, R.; Heng, H. H.; George, S. R.; O'Dowd, B. F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, GPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res. Mol. Brain Res. 1999, 64, 193.
8. Wise, A.; Brown, A.J. Glaxosmithkline. WO0186305, 2001.
9. Drmota, T.; Greasley, P.; Groblewski, T. AstraZeneca. WO04074844, 2004.
10. Glucksmann, M. A.; Weich, N. Millennium Pharmaceuticals Inc., WO990023588, 1999.
11. Lauckner, J. E.; Jensen, J. B.; Chen, H. Y.; Lu, H. C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. USA 2008, 105, 2699.
12. 2+ signaling and NFAT activation. FASEB J. 2008, 23, 183.
13. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N. O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P. J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 2007, 152, 1092.
14. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; Sugiura, T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: possible natural ligand for GPR55. J. Biochem. 2009, 145, 13.
15. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 2007, 362, 928.
16. Ross, R.A. The enigmatic pharmacology of GPR55. Trends Pharmacol. Sci. 2009, 30, 156.
17. Staton, P. C.; Hatcher, J. P.; Walker, D. J.; Morrison, A. D.; Shapland, E. M.; Hughes, J. P.; Chong, E.; Mander, P. K.; Green, P. J.; Billinton, A.; Fulleylove, M.; Lancaster, H. C.; Smith, J. C.; Bailey, L. T.; Wise, A.; Brown, A. J.; Richardson, J. C.; Chessell, I. P. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008, 139, 225.
18. Pietr, M.; Kozela, E.; Levy, R.; Rimmerman, N.; Lin, Y. H.; Stella, N.; Vogel, Z.; Juknat, A. Differential changes in GPR55 during microglial cell activation. FEBS Lett. 2009, 583, 2071.
19. Offertaler, L.; Mo, F. M.; Batkai, S.; Liu, J.; Begg, M.; Razdan, R. K.; Martin, B.R.; Bikoski, R. D.; Kunos, G. Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid Receptor. Mol. Pharmacol. 2003, 63, 699.
20. Johns, D. G.; Behm, D. J.; Walker, D. J.; Ao, Z.; Shapland, E. M.; Daniels, D. A.; Riddick, M.; Dowell, S.; Staton, P. C.; Green, P.; Shabon, U.; Bao, W.; Aiyar, N.; Yue, T. L.; Brown, A. J.; Morrison, A. D.; Douglas, S. A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 2007, 152, 825.
21. 21 Annual symposium of the International Cannabinoid Research Society, Scotland, 2008.
22. Kenakin, T. P.; Onaran, O. The ligand paradox between affinity and efficacy: can you be there and not make a difference? Trends Pharmacol. Sci. 2002, 23, 275.
23. Kenakin, T. P. Efficacy at G protein coupled receptors. Nat. Rev. Drug Discov. 2002, 1, 103.
24. Kenakin, T. P. Agonist-receptor efficacy II: agonist trafficking of receptor signals. Trends Pharmacol. Sci. 1995, 16, 232.
25. Kenakin, T. P. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat. Rev. Drug Discov. 2009, 8, 617.
26. Urban, J.D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007, 320, 1.
27. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M. G.; Barak, L. S.; Abood, M. E. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem. 2009, 284, 29817.
28. 2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J. Cell Sci. 2008, 121, 1704.
29. Begg, M.; Pacher, P.; Batkai, S.; Osei-Hyiaman, D.; Offertaler, L.; Mo, F. M.; Liu, J.; Kunos, G. Evidence for novel cannabinoid receptors. Pharmacol. Ther. 2005, 106, 133.
30. Fox, A.; Bevan, S. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert Opin. Invest. Drugs. 2005, 14, 695.
31. Beltramo, M. Cannabinoid Type 2 receptor as a target for chronicpain. Mini-Rev. Med. Chem. 2009, 9, 11.
32. Puig, S.; Sorkin, L. S. Formalin-evoked activity in identified primary afferent fibers: Systemic lidocaine suppresses phase-2 activity. Pain 1996, 64, 345.
33. Neumann, S.; Doubell, T. P.; Leslie, T.; Woolf, C. J. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature 1996, 384, 360.
34. Ruscheweyh, R.; Forsthuber, L.; Schoffnegger, D.; Sandkuhler, J. Modification of classical neurochemical markers in identified primary afferent neurons with Abeta-, Adelta-, and C-fibers after chronic constriction injury in mice. J. Comp. Neurol. 2007, 502, 325.
35. Lauckner, J. E.; Hille, B.; Mackie, K. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. USA 2005, 102,19144.
36. Verri, J.; Cunha, T. M.; Parada, C. A.; Poole, S.; Cunha, F. Q.; Ferreira, S. H. Hypernociceptive role of cytokines and chemokines: targets for analgesic drug development? Pharmacol. Ther. 2006, 112, 116.
37. George, A.; Kleinschnitz, C.; Zelenka, M.; Brinkhoff, J.; Stoll, G.; Sommer, C. Wallerian degeneration after crush or chronic constriction injury of rodent sciatic nerve is associated with a depletion of endoneurial interleukin-10 protein. Exp. Neurol. 2004, 188, 187.
38. Vale, M. L.; Marques, J. B.; Moreira, C. A.; Rocha, F. A. C.; Ferreira, S. H.; Poole, S. Antinociceptive effects of interleukin-4, -10, and -13 on the writhing response in mice and zymosan-induced knee joint incapacitation in Rats. J. Pharmacol. Exp. Ther. 2003, 304, 102.
39. Stella, N. Endocannabinoid signaling in microglial cells. Neuropharmacology 2009, 56, 244.
40. Carlisle, S. J., Marciano-Cabral, F., Staab, A., Ludwick, C., Cabral, G. A. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. Int. Immunopharmacol. 2002, 2, 69.
41. Rock, R.B.; Gekker, G.; Hu, S.; Sheng, W.S.; Cabral, G.A.; Martin, B.R.; Peterson, P.K. WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors. J. Neuroimmune Pharmacol. 2007, 2, 178.
42. Gardner, B., Zu, L.X., Sharma, S., Liu, Q., Makriyannis, A., Tashkin, D., Dubinett, S. M. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-β. Biochem. Biophys. Res. Commun. 2002, 290, 91.
43. Carayon, P.; Marchand, J.; Dussossoy, D.; Derocq, J. M.; Jbilo, O.;, Bord, A.; Bouaboula, M.; Galiegue, S.; Mondiere, P.; Penarier, G.; LeFur, G.; Defrance, T.; Casellas, P. Modulation and functional involvement of CB2 peripheral cannabinoid receptors during B-cell differerntiation. Blood 1998, 92, 3605.
44. Lee, S. F.; Newton, C.; Widen, R.; Friedman, H.; Klein, T.W. Differential expression of cannabinoid CB2 receptor mRNA in mouse immune cell subpopulation and following B cell stimulation. Eur. J. Pharmacol. 2001, 423, 235.
45. Maresz, K.; Carrier, E. J.; Ponomarev, E. D.; Hillard, C.J.; Dittel, B. N. Modulation of the cannabinoid CB receptor in microglial cells in response to inflammatory stimuli. J. Neurochem. 2005, 95, 437.
46. Whyte, L. S.; Ryberg, E.; Sims, N. A.; Ridge, S. A.; Mackie, K.; Greasley, P. J.; Ross, R. A.; Rogers, M. J. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc. Natl. Acad. Sci. USA 2009, 106, 16511.
47. Bab, I.; Zimmer, A. Cannabinoid receptors and the regulation of bone mass. Br. J. Pharmacol. 2008, 153, 182.
48. Ofek, O.; Karsak, M.; Leclerc, N.; Fogel, M.; Frenkel, B.; Wright, K. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. USA 2006, 103, 696.
49. Karsak, M.; Cohen-Solal, M.; Freudenberg, J.; Ostertag, A.; Morieux, C.; Kornak, U. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum. Mol. Genet. 2005, 14, 3389.
50. Yin, H.; Chu, A.; Li, W.; Wang, B.; Shelton, F.; Otero, F.; Nguyen, D. G.; Caldwell, J. S.; Chen, Y. A. Lipid G-protein-coupled receptor ligand identification using beta -arrestin Pathhunter assay. J. Biol. Chem. 2009, 284, 12328.
51. Calignano, A.; La Rana, G.; Giuffrida, A.; Piomelli, D. Control of pain initiation by endogenous cannabinoids. Nature 1998, 394, 277. (Pubitemid 28335039)
52. Mechoulam, R. Marihuana chemistry. Science 1970, 168, 1159.
53. Mechoulam, R.; Shani, A.; Edery, H.; Grunfeld, Y. Chemical basis of hashish activity. Science 1970, 169, 611.
54. Huffman, J. W.; Liddle, J.; Yu, S.; Aung, M. M.; Abood, M. E.; Wiley, J. L.; Martin, B. R. 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem. 1999, 7, 2905.
55. Howard, A. D.; McAllister, G.; Feighner, S. D.; Liu, Q.; Nargund, R. P.; Van der Ploeg, L. H.; Patchett, A. A. Orphan G-protein-coupled receptors and natural ligand discovery. Trends Pharmacol. Sci. 2001, 22, 132.
56. Gether, U. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Endocr. Rev. 2000, 21, 90.
57. Sakmar, T. P.; Menon, S.T.; Marin, E. P.; Awad, E. S. Rhodopsin: Insights from recent structural studies. Annu. Rev. Biophys. Biomol. Struct. 2002, 31, 443.
58. Protein Data Bank (PDB): http://www.rcsb.org/pdb/home/home.do
59. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G.; Thian, F. S.; Kobilka, T. S.; Choi, H. J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-resolution crystal structure of an engineered human beta2-adrenergic G-protein-coupled receptor. Science 2007, 318, 1258.
60. Jaakola, V. P.; Griffith, M. T.; Hanson, M. A.; Cherezov, V.; Chien, E. Y.; Lane, J. R.; Ijzerman, A. P., Stevens, R. C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322, 1211.
61. Hopkins, A. L.; Groom, C. R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1, 727.
62. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; Salzberg, C.; Huang, E. S. Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. 2007, 25, 71.
63. Brown, A. J. Novel cannabinoid receptors. Br. J. Pharmacol. 2007, 152, 567.
64. GenBank http://www.ncbi.nlm.nih.gov/Genbank/index.html
65. Sawzdargo, M.; George, S. R.; Nguyen, T.; Xu, S.; Kolakowski, L. F.; O' Dowd, B. F. A cluster of four novel human G protein-coupled receptor genes occurring in close proximity to CD22 gene on chromosome 19q13.1 Biochem. Biophys. Res. Commun. 1997, 239, 543.
66. Strausberg, R. L.; Feingold, E. A.; Grouse, L. H.; Derge, J. G.; Klausner, R. D.; Collins, F. S.; Wagner, L.; Shenmen, C. M.; Schuler, G. D.; Altschul, S. F.; Zeeberg, B.; Buetow, K. H.; Schaefer, C. F.; Bhat, N. K.; Hopkins, R. F.; Jordan, H.; Moore, T.; Max, S. I.; Wang, J.; Hsieh, F.; Diatchenko, L.; Marusina, K.; Farmer, A. A.; Rubin, G. M.; Hong, L.; Stapleton, M.; Soares, M. B.; Bonaldo, M. F.; Casavant, T. L.; Scheetz, T. E.; Brownstein, M. J.; Usdin, T. B.; Toshiyuki, S.; Carninci, P.; Prange, C.; Raha, S. S.; Loquellano, N. A.; Peters, G. J.; Abramson, R. D.; Mullahy, S. J.; Bosak, S. A.; McEwan, P. J.; McKernan, K. J.; Malek, J. A.; Gunaratne, P. H.; Richards, S.; Worley, K. C.; Hale, S.; Garcia, A. M.; Gay, L. J.; Hulyk, S. W.; Villalon, D. K.; Muzny, D. M.; Sodergren, E. J.; Lu, X.; Gibbs, R. A.; Fahey, J.; Helton, E.; Ketteman, M.; Madan, A.; Rodrigues, S.; Sanchez, A.; Whiting, M.; Madan, A.; Young, A. C.; Shevchenko, Y.; Bouffard, G. G.; Blakesley, R. W.; Touchman, J. W.; Green, E. D.; Dickson, M. C.; Rodriguez, A. C.; Grimwood, J.; Schmutz, J.; Myers, R. M.; Butterfield. Y. S.; Krzywinski, M. I.; Skalska, U.; Smailus, D. E.; Schnerch, A.; Schein, J. E.; Jones, S. J.; Marra, M. A. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc. Natl. Acad. Sci. USA 2002, 99, 16899.
67. Baker, D.; Pryce, G.; Davies, W. L.; Hiley, C. R. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 2006, 27,1.
68. Allegretti, M.; Moriconi, A.; Beccari, A. R.; Di Bitondo, R.; Bizzarri, C.; Bertini, R.; Colotta, F. Targeting C5a: recent advances in drug discovery. Curr. Med. Chem. 2005, 12, 217. (Pubitemid 40089835)
69. Petitet, F.; Donlan, M.; Michel, A. GPR55 as a new cannabinoid receptor: still a long way to prove it. Chem. Biol. Drug Des. 2006, 67, 252.
70. Ballesteros, J. A.; Palczewski, K. G protein-coupled receptor drug discovery: Implications from the crystal structure of rhodopsin. Curr. Opin. Drug Discov. Dev. 2001, 4, 561. (Pubitemid 32904854)
71. Flanagan, C. A.; Zhou, W.; Chi, L.; Yuen, T.; Rodic, V.; Robertson, D.; Johnson, M.; Holland, P.; Millar, R. P.; Weinstein, H.; Mitchell, R.; Sealfon, S. C. The functional microdomain in transmembrane helices 2 and 7 regulates expression, activation, and coupling pathways of the gonadotropin-releasing hormone receptor. J. Biol. Chem. 1999, 274, 28880.
72. Sealfon, S. C.; Chi, L.; Ebersole, B. J.; Rodic, V.; Zhang, D.; Ballesteros, J. A.; Weinstein, H. Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT graphic receptor. J. Biol. Chem. 1995, 270, 16683.
73. Wilson, M. H.; Highfield, H. A.; Limbird, L. E. The role of a conserved inter-transmembrane domain interface in regulating alpha(2a)-adrenergic receptor conformational stability and cellsurface turnover. Mol. Pharmacol. 2001, 59, 929.
74. Xu, W.; Ozdener, F.; Li, J. G.; Chen, C.; de Riel, J. K.; Weinstein, H.; Liu-Chen, L.Y. Functional role of the spatial proximity of Asp114(2.50) in TMH 2 and Asn332(7.49) in TMH 7 of the μ opioid receptor. FEBS Lett. 1999, 447, 318
75. McAllister, S. D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D. P.; Barnett- Norris, J.; Lynch, D. L.; Reggio, P. H.; Abood, M. E. An aromatic microdomain at the cannabinoid CB1 receptor constitutes an agonist/inverse agonist binding region. J. Med. Chem. 2003, 46, 5139.
76. Horuk, R. Chemokine receptor antagonist: overcoming developmental hurdles. Nat. Rev. Drug Discov. 2009, 8, 23.